Infinity and MedImmune Announce Updated Data On Ipi-504 to be,Presented At ASCO ( zymes (kinases) calledKIT or PDGFRA ...)

Infinity and MedImmune Announce Updated Data On Ipi-504 to be,Presented At ASCO

zymes ("kinases") called KIT or PDGFRA cause the growth and survival signal of the cell to become permanently active, leading to cancer. Both KIT and PDGFRA are client proteins of Hsp90, suggesting that inhibition of Hsp90 in GIST is an attractive area for clinical study.

About Infinity -- MedImmune Collaboration

In August 2006, Infinity and MedImmune entered into an agreement to jointly develop and commercialize novel small molecule cancer drugs targeting Hsp90 and the Hedgehog cell-signaling pathway. The collaboration is focused on inhibitors of Hsp90, including IPI-504 which is in Phase I/II clinical trials, as well as next-generation oral versions of IPI-504, and a series of molecules targeting the Hedgehog cell signaling pathway.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. For more information on Infinity, please refer to the company's website at http://www.ipi.com.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.

Forward-Looking Statements

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

Post Your Comments:

(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 Decision ... for pharmaceutical and healthcare issues, finds that, over the past ... ( France , Germany , ... and the United Kingdom ) have been ... most of their HIV patients, primarily to reduce costs. Additionally, ...

(Date:6/18/2013)... -- Today, Wall Street Reports announced new research ... Health Management Associates Inc. (NYSE: HMA ), IDEXX ... (NASDAQ: ISIS ), and Trius Therapeutics Inc. (NASDAQ: ... - including full price targets, industry analysis and analyst ratings ... Research Report On June 7, 2013, Gilead Sciences ...

(Date:6/18/2013)... , June 18, 2013 Apama Medical, ... the development of next-generation atrial fibrillation technologies, today ... by the US Patent and Trademark Office (USPTO), ... profile electrode assemblies for use on expandable structures ... other surgical procedures. "We are grateful ...

Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2 One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6

[0] One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs [0] Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics [0] Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons

... EVEN MORE SCIENCE SUPPORTING THE, THEORY THAT ... Mo., May 19 A primate model for ... at the,International Meeting For Autism Research (IMFAR) this ... into vaccine safety and,the immune and mitochondrial dysfunction ...

... Native Bladder by Six Months; Data Presented at May 18 Press ... ... ORLANDO, Fla. and EAST NORRITON, Pa., May 19 Tengion,Inc., a ... presented preclinical efficacy data for its,Tengion Neo-Bladder Replacement(TM) at the Annual ...

Cached Medicine Technology:UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism 2 Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2

UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)

(Date:6/18/2013)... Petersburg, FL (PRWEB) June 19, 2013 ... 5 minutes a day could boost your health and ... Kathy Heshelow, founder of Sublime Beauty®. "It is called ... practiced for centuries but became a lost art. Now, ... celebrities know about Skin Brushing, and so do certain ...

(Date:6/18/2013)... June 19, 2013 An apple a ... Christina Beauregard was diagnosed with breast cancer, she chose ... new book, “I Gave Myself Cancer, I Can Take ... by Balboa Press), Beauregard explains how changing her physical, ... "Sick people have been made to feel fearful when ...

(Date:6/18/2013)... June 18, 2013 Daily Gossip Magazine has ... reviews and useful articles. , The magazine has decided ... to a new anabolic recipe every week . ... is the perfect guide for readers who are looking to ... at Daily Gossip reveals that anabolic food is almost entirely ...

(Date:6/18/2013)... 19, 2013 The Drug Delivery Partnering ... access to the drug delivery partnering deals and agreements ... , The report provides a detailed understanding and analysis ... deals. The majority of deals are discovery or development ... option right to license the license drug delivery technology. ...

(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...

Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2 Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2 Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3 Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4 Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2

[0] The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty®[0] Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method [0] Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders [0] New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz [0] Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting

... Inc. (NYSE:,CVD), a leading provider of drug development ... Merck & Co., Inc.,s Outstanding,Strategic Collaboration Award., ... 12 suppliers who,were selected from thousands of Merck ... performance; contributions towards the Key,Business Result (KBR) for ...

... GXDX ), a specialized laboratory services provider, today reported,revenues ... and $50.1 million,for the first half of 2008, as ... the respective periods in 2007. Stated revenue for the,first ... changes in,accounting estimates relating to prior periods., "Our ...

... mortality 25% in chronic kidney cases , , THURSDAY, July ... -- a routinely measured marker of bone disease -- ... receiving dialysis for chronic kidney disease, say U.S. researchers. ... patients during a three-year period. It found that patients ...

... COMMERCIAL LAUNCH OF HEARTMATE II(R) ... FOR BRIDGE-TO-TRANSPLANTATION, PLEASANTON, Calif., July 31 ... support therapies to save, support and restore failing hearts,today said that ... in the same period a year ago., Revenues for the ...

... she had hearing loss at 30, when she volunteered to ... sounds she could not hear. , Her husband Larry, ... history. Her mother, grandfather and great-grandfather had severe hearing loss ... before he reached school age. , The hearing loss ...

... 31 HealthSouth,Corporation (NYSE: HLS ) ... owned,subsidiaries, its previously announced purchase of The ... rehabilitation hospital in,Vineland, NJ, from The Mediplex/Cumberland ... South Jersey, under the outstanding,leadership of Dr. ...

Covance Recognized for Outstanding Performance by Merck & Co., Inc.Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 Bone Disease Test Shows Death Risk for Dialysis Patients Thoratec Reports 44 Percent Increase in Second Quarter Revenues;Inherited form of hearing loss stems from gene mutation HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital

Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....

For the quantitative determination of iron, total iron-binding capacity in human serum....

HDL Cholesterol, liquid....

Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...

Medicine Products:

Iron / TIBC (Ferrozine)Iron/TIBC Reagent Set HDL Cholesterol (Precipitation)HDL-Cholesterol Direct Reagent